Results 31 to 40 of about 95,754 (365)

Primary biliary cholangitis presenting as acute ischemic stroke: A rare association

open access: yesClinical Case Reports, 2020
Primary biliary cholangitis is associated with hyperlipidemia, but studies show that the condition does not increase cardiovascular risks. The case presents acute ischemic stroke with no underlying risk factors and subsequent new diagnosis of primary ...
Bumsoo Park   +3 more
doaj   +1 more source

Multiple therapeutic targets in rare cholestatic liver diseases: Time to redefine treatment strategies

open access: yesAnnals of Hepatology, 2020
Primary biliary cholangitis and primary sclerosing cholangitis are rare diseases affecting the bile ducts and the liver. The limited knowledge of their pathogenesis leads to limited therapeutic options.
Alessio Gerussi   +5 more
doaj   +1 more source

Primary Sclerosing Cholangitis Complicated with Aphthoid Colitis Difficult to Diagnose from IgG4-Related Sclerosing Cholangitis

open access: yesCase Reports in Gastroenterology, 2022
A 19-year-old man visited our hospital because of diarrhea and blood and liver dysfunction. Magnetic and endoscopic retrograde cholangiography revealed diffuse narrowing of the common biliary tract and intrahepatic biliary tract.
Jin Imai   +8 more
doaj   +1 more source

Interleukin‐18 signaling promotes activation of hepatic stellate cells in mouse liver fibrosis

open access: yesHepatology, EarlyView., 2022
Interleukin‐18 signaling promotes activation of hepatic stellate cells in mouse liver fibrosis. Abstract Background and Aims Nucleotide‐binding oligomerization domain‐like receptor‐family pyrin domain‐containing 3 (NLRP3) inflammasome activation has been shown to result in liver fibrosis.
Jana Knorr   +19 more
wiley   +1 more source

Guidelines on the Diagnosis and Management of Primary Biliary Cholangitis (2021)

open access: yesJournal of Clinical and Translational Hepatology, 2023
In 2015, the Chinese Society of Hepatology and the Chinese Society of Gastroenterology published a consensus on primary biliary cholangitis (PBC). In the past years, numerous clinical studies have been published in the field of PBC. To guide the clinical
H. You   +13 more
semanticscholar   +1 more source

Serum bile acids as a prognostic biomarker in biliary atresia following Kasai portoenterostomy

open access: yesHepatology, EarlyView., 2022
Serum bile acid levels predict outcomes in patients with biliary atresia who achieve normalized bilirubin levels after Kasai portoenterostomy. Abstract Background and Aims In biliary atresia, serum bilirubin is commonly used to predict outcomes after Kasai portoenterostomy (KP).
Sanjiv Harpavat   +22 more
wiley   +1 more source

Effect of stent placement on stone recurrence and post-procedural cholangitis after endoscopic removal of common bile duct stones [PDF]

open access: yesThe Korean Journal of Internal Medicine, 2021
Background/Aims After endoscopic treatment of common bile duct (CBD) stones, recurrence of choledocholithiasis due to small stone fragments and post-endoscopic retrograde cholangiopancreatography (post-ERCP) cholangitis can occur.
Jung-Hye Choi   +2 more
doaj   +1 more source

Management of Primary Biliary Cholangitis: Current Treatment and Future Perspectives

open access: yesThe Turkish Journal of Gastroenterology, 2023
Primary biliary cholangitis is an autoimmune cholestatic liver disease characterized by progressive destruction of bile ducts, which can ultimately progress to chronic liver disease and cirrhosis.
Romelia Barba Bernal   +7 more
semanticscholar   +1 more source

P-105 PREVALENCE OF ANTIMITOCHONDRIAL ANTIBODIES IN PATIENTS WITH PRIMARY BILE CHOLANGITIS AND ITS OUTCOME IN LIVER TRANSPLANTATION

open access: yesAnnals of Hepatology, 2021
Introduction: The presence of antimitochondrial antibodies has been described as a diagnostic criterion for primary biliary cholangitis. However, no studies have been established in the South American population to describe the prevalence of these ...
Andres Gomez Aldana   +5 more
doaj   +1 more source

Open‐label, clinical trial extension: Two‐year safety and efficacy results of seladelpar in patients with primary biliary cholangitis

open access: yesAlimentary Pharmacology and Therapeutics, 2023
Seladelpar is a potent and selective peroxisome proliferator‐activated receptor‐δ agonist that targets multiple cell types involved in primary biliary cholangitis (PBC), leading to anti‐cholestatic, anti‐inflammatory and anti‐pruritic effects.
M. Mayo   +22 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy